ClinicalTrials.gg
CompletedNCT04800237Updated Mar 20, 2024

Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety

A Phase 2 interventional study of VQW-765 and Placebo in Performance Anxiety, sponsored by Vanda Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 187 studies in Phobia, Social with a site in United States — 23 open to participants now, 29 under way, 1 of them phase 3. Phobia, Social · United States.

Enrollment
28th of 178
230 · median 64
Started
2021
with 5 others
Phase 2
25 of 187
2 open now
Registered
129th of 187
by date

Among the 187 studies in Phobia, Social with a site in United States, this one is the 28th largest by enrollment of the 178 interventional ones that give a count, is one of 6 that started in 2021, is one of 25 in phase 2, and was the 129th registered.

Phobia, Social

368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.

Browse Phobia, Social studies →

Open to participants now

23 of the 187 studies in Phobia, Social with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Phobia, Social with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.

03

Conditions studied

  • Performance Anxiety

Browse trials for

Keywords

  • social phobia
  • social anxiety disorder
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability and willingness to provide written .
  • Sufficiently fluent in English to participate in the trial.
  • Male and female patients aged 18-70 years (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Lifetime history of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders or obsessive-compulsive disorder.
  • Current or planned pregnancy or nursing during the trial period.
  • A positive test for substances of abuse.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    VQW-765

    Drug: VQW-765

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugVQW-765

    oral capsule

  • DrugPlacebo

    oral capsule

06

What researchers measure

Primary outcomes

  1. Subjective Units of Distress Scale (SUDS)

    Time frame: 1 Day

Secondary outcomes

  1. Clinician Global Impression of Change (CGI-C) scale at visit 2

    Time frame: 1 Day

  2. Patient Global Impression of Change (PGI-C) scale at visit 2

    Time frame: 1 Day

  3. Assessment of safety and tolerability of a single dose of VQW-765, as measured by spontaneous reporting of adverse events (AEs)

    Time frame: 1 Day

07

Study locations

15 sites
  • Vanda Investigational Site
    Tempe, Arizona 85281, United States
  • Vanda Investigational Site
    Beverly Hills, California 90212, United States
  • Vanda Investigational Site
    Garden Grove, California 92845, United States
  • Vanda Investigational Site
    San Jose, California 95124, United States
  • Vanda Investigational Site
    Torrance, California 90502, United States
  • Vanda Investigational Site
    Orlando, Florida 32816, United States
  • Vanda Investigational Site
    Boston, Massachusetts 02114, United States
  • Vanda Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • Vanda Investigational Site
    Las Vegas, Nevada 89119, United States
  • Vanda Investigational Site
    Berlin, New Jersey 08009, United States
  • Vanda Investigational Site
    New York, New York 10016, United States
  • Vanda Investigational Site
    Staten Island, New York 10312, United States
  • Vanda Investigational Site
    Raleigh, North Carolina 27612, United States
  • Vanda Investigational Site
    Cincinnati, Ohio 45212, United States
  • Vanda Investigational Site
    Houston, Texas 77074, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Aug 2022, 17 months.

Of 15 phase 2 interventional studies under Phobia, Social, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 17 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2021
First posted
Mar 16, 2021
StartActual
Feb 23, 2021
Primary completionActual
Aug 2, 2022
CompletionActual
Aug 2, 2022
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04800237
Responsible party
Sponsor
First posted
Mar 16, 2021
Start date
Feb 23, 2021
Primary completion
Aug 2, 2022
Completion
Aug 2, 2022
Last update
Mar 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion